SXC Health Solutions, Inc. (SXCI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SXC Health Solutions, Inc. (SXCI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: JakeStraw	5/6/2010 8:03:51 AM
	of 61

SXC Health solutions announces first quarter financial results finance.yahoo.com Q1 2010 Highlights ------------------ - Revenue was $452.1 million compared to $291.0 million in Q1 2009 - Gross profit was $50.2 million compared to $39.2 million in Q1 2009 - Adjusted EBITDA(1) was $27.7 million compared to $16.3 million in Q1 2009 - GAAP net income increased to $14.8 million, or $0.48 per share (fully-diluted), compared to $7.7 million, or $0.31 per share (fully- diluted), in Q1 2009 - Non-GAAP adjusted EPS(1) (diluted), which excludes the NMHC transaction-related amortization, was $0.51 compared to $0.38 in Q1 2009 - Adjusted prescription claim volume(1) for the PBM segment was 11.7 million compared to 8.4 million in Q1 2009 - Mail order penetration was 11% compared to 8% in Q1 2009 - Transaction processing volume for the HCIT segment was 99.5 million in Q1 2010 compared to 96.8 million in Q1 2009 - Announced a multi-year PBM contract with HealthSpring Inc. valued at $1 billion annually starting January 1, 2011 - Renewed a five-year PBM contract with the Boston Medical Center HealthNet (BMC) - Awarded full pharmacy benefit management accreditation from URAC, a Washington, DC-based health care accreditation organization - Went live with Spectral Solutions, LLC, valued at $50 million annually 010 Full Year Financial Guidance With today's announcement, SXC is revising certain of its 2010 full year financial targets for: - Revenue of $1.9 to $2.0 billion, unchanged - Gross profit of $198 to $208 million versus prior estimate of $195 to $205 million - Adjusted EBITDA of $111 to $115 million versus prior estimate of $108 to $112 million - Fully-diluted GAAP EPS (including all transaction-related amortization) of $1.84 to $1.92 versus prior estimate of $1.79 to $1.87 - Fully-diluted Non-GAAP adjusted EPS(1) (excluding the NMHC transaction-related amortization) of $1.96 to $2.05 versus prior estimate of $1.92 to $2.00

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next